LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

Home・Elenco Azioni・Cytokinetics Inc

Cytokinetics Inc

Aperta

SettoreSettore sanitario

70.45 -1.03

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

70.2

Massimo

71.64

Metriche Chiave
By Trading Economics
Entrata	-23M -206M
Vendite	1.6M 19M
EPS	-1.67
Margine di Profitto	-1,064.485
Dipendenti	673
EBITDA	112K -180M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+41.52% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	2.2B 10B
Apertura precedente	71.48
Chiusura precedente	70.45

Notizie sul Sentiment di mercato

By Acuity

50%

147 / 344 Classifica in Healthcare

Cytokinetics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 giu 2026, 20:30 UTC

Utili

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 giu 2026, 23:58 UTC

Discorsi di Mercato

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 giu 2026, 23:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 giu 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 giu 2026, 23:41 UTC

Discorsi di Mercato

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 giu 2026, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 giu 2026, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 giu 2026, 23:00 UTC

Acquisizioni, Fusioni, Takeovers

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 giu 2026, 22:57 UTC

Discorsi di Mercato

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 giu 2026, 22:50 UTC

Discorsi di Mercato

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 giu 2026, 21:07 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

2 giu 2026, 21:07 UTC

Discorsi di Mercato

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 giu 2026, 21:00 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

2 giu 2026, 20:46 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:38 UTC

Utili

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 giu 2026, 20:21 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:12 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Product Rev $594M

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Loss $177M >PANW

Confronto tra pari

Modifica del prezzo

Cytokinetics Inc Previsione

Obiettivo di Prezzo

By TipRanks

41.52% in crescita

Previsioni per 12 mesi

Media 100.35 USD 41.52%

Alto 140 USD

Basso 67 USD

Basato su 18 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cytokinetics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

18 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 18 che hanno fornito valutazioni azionarie a Cytokinetics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

147 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.